CEL-SCI Corporation (NYSE American: CVM) said on July 13, 2026, that it is launching a global, 212-patient Phase 3 confirmatory registration study of Multikine, an investigational neoadjuvant immunotherapy for newly diagnosed, previously untreated, resectable, locally advanced squamous cell carcinoma of the head and neck. The randomized study will compare Multikine followed by standard care with standard care alone in patients whose tumors have low or zero PD-L1 expression and who have no clinical lymph-node involvement at enrollment. Multikine has not been approved by the United States Food and Drug Administration or any other regulator, and its efficacy and safety have not been established for commercial use.
The launch moves CEL-SCI beyond protocol preparation and toward the prospective test that regulators have required. Enrollment is expected through clinical centers in the United States, Europe and Asia, followed later by South America, while Orient EuroPharma will oversee and finance enrollment in its Taiwanese territory.
The central issue is not whether CEL-SCI found an encouraging signal in its earlier development programme. It did. The more consequential question is whether a relatively small, biomarker-selected Phase 3 study can reproduce a large survival difference that emerged within a narrower population from a much broader trial whose primary overall-survival analysis was not statistically significant.
What is genuinely new about CEL-SCI’s 212-patient Multikine confirmatory study?
The announcement represents a transition from regulatory planning to global trial launch, although CEL-SCI has not yet reported that the first patient has been dosed. Site activation, public registration of the final protocol and the beginning of screening will therefore be the next operational evidence that the programme has entered active clinical execution.
The new Phase 3 study is designed around approximately 212 patients, fewer than one-quarter of the enrollment in CEL-SCI’s earlier trial. Participants must have resectable, locally advanced primary head and neck cancer, no clinically detectable lymph-node involvement at entry and low or zero tumor PD-L1 expression.
Those criteria are intended to identify before treatment the population in which CEL-SCI reported its strongest survival results. This is an important design improvement because the earlier trial’s low-risk classification depended partly on pathological information obtained during surgery. A registration study cannot depend on discovering the target population only after treatment has already been assigned. The use of pre-treatment biopsy and imaging, including positron emission tomography to assess lymph-node involvement, is intended to make the selection strategy prospective and reproducible.
CEL-SCI said the study has approximately 97% statistical power to detect the previously observed overall-survival hazard ratio of about 0.34. That sounds reassuring, but statistical power depends on the assumed treatment effect being reasonably close to reality. A study powered around a very large benefit may become less decisive if the true effect is more moderate.
Why does the earlier Multikine Phase 3 result require careful interpretation?
The original IT-MATTERS study was substantial by biotechnology standards. It randomized 928 patients across multiple countries, with 923 included in the intent-to-treat analysis, and evaluated a three-week Multikine treatment regimen before surgery and subsequent radiotherapy or chemoradiotherapy.
The primary efficacy endpoint was overall survival in the full intent-to-treat population. That analysis did not achieve statistical significance, with the peer-reviewed report giving a two-sided log-rank p-value of 0.41. Describing the earlier study simply as a successful Phase 3 trial would therefore conceal the most important regulatory fact.
The study nevertheless generated a statistically significant overall-survival result in the prospectively defined low-risk population that received Multikine with the supporting treatment regimen and standard care. In that analysis, the reported hazard ratio was 0.68, while five-year survival was 62.7% with the Multikine regimen and 48.6% with standard care alone.
CEL-SCI subsequently refined the target further using PD-L1 expression and clinical lymph-node status. In the 114 Multikine-treated patients meeting the current target characteristics, the company reported five-year overall survival of 73%, compared with 45% in corresponding control patients, with a hazard ratio of approximately 0.34 to 0.35. The company also reported a 13% presurgical objective response rate against zero in controls and downstaging in 35% of Multikine-treated patients compared with 13% of controls.
These are potentially meaningful differences, particularly because overall survival is an unambiguous patient outcome. However, the exact population now being targeted is more selective than the population originally used for the primary analysis. The 212-patient study must prospectively confirm that the selection criteria identify patients who benefit, rather than patients whose historical results appeared unusually favorable within a larger dataset.
The earlier findings have been published in a peer-reviewed journal, which provides more evidentiary weight than a press release or conference abstract alone. The publication also disclosed that CEL-SCI funded, designed and oversaw the study, with company employees among the authors. The data are therefore available for scientific examination, but independent prospective replication remains essential.
Could presurgical tumor response support an accelerated Multikine approval application?
CEL-SCI plans to assess objective tumor responses and tumor downstaging after the three-week presurgical treatment period. Management has indicated that these early findings could support an accelerated approval application while blinded overall-survival follow-up continues until the required number of events has accumulated.
This strategy could shorten the time between full enrollment and a regulatory submission, but accelerated approval is not automatic. The United States Food and Drug Administration would need to accept the presurgical endpoint as a surrogate that is reasonably likely to predict clinical benefit in this specific disease, setting and population.
The earlier study found an association between objective early response and longer survival. Responders had better outcomes than non-responders and control patients, while pathological confirmation at surgery strengthened the response assessment. Association, however, is not necessarily validation of a surrogate endpoint. Patients who respond quickly may also possess favorable disease biology or immune characteristics that independently contribute to longer survival.
The confirmatory study can address this uncertainty by testing whether Multikine increases the presurgical response rate against a randomized control and whether that difference is followed by improved survival. Regulators may also examine response definitions, central pathology review, imaging consistency, missing assessments and whether the early endpoint performs similarly across regions.
The FDA’s previous indication that CEL-SCI may proceed with the study means the proposed clinical investigation can move forward. It does not amount to Multikine approval, confirmation that the trial will succeed or a commitment that an accelerated approval application will be accepted.
How has pembrolizumab changed the competitive setting for Multikine?
The treatment environment has moved since CEL-SCI’s original Phase 3 programme began. In June 2025, the United States Food and Drug Administration approved Merck & Co., Inc.’s Keytruda, or pembrolizumab, for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 at a combined positive score of at least one.
That regimen uses pembrolizumab before surgery, continues it alongside postoperative radiotherapy with or without cisplatin and then maintains pembrolizumab as a single agent. Multikine is being developed as a three-week local and regional immunotherapy administered before conventional treatment, after which patients proceed to surgery and risk-appropriate standard care.
CEL-SCI has emphasized patients with low or zero PD-L1 expression, but this should not be interpreted as a completely separate commercial population. Patients with zero expression may fall outside the pembrolizumab perioperative label, while some patients described as having low expression could still have a combined positive score of at least one and therefore overlap with the approved Keytruda population. The Multikine study’s assay, cutoff and biomarker definition will be important when determining the eventual addressable population.
Cross-trial comparisons between Multikine and pembrolizumab would also be unreliable. The programmes use different eligibility criteria, treatment durations, endpoints, biomarker definitions and postoperative regimens. Multikine will need to establish its own benefit-risk profile rather than relying on the argument that low PD-L1 automatically produces an uncontested market.
If the confirmatory study succeeds, a short treatment course completed before surgery could become a practical differentiator. That potential advantage must still be balanced against administration complexity, the requirement for repeated peritumoral and perilymphatic injections and the need to complete screening without unnecessarily delaying definitive surgery.
Will the three-week treatment window fit safely into head and neck cancer workflows?
Multikine is a cell-free biological mixture containing cytokines and other immune-signalling proteins. In the earlier study, it was administered locally and near lymphatic drainage areas over three consecutive weeks before surgery.
The peer-reviewed safety analysis reported injection-site pain and injection-site bleeding among the more frequent presurgical events. These events resolved, and the investigators reported that they did not prevent surgery or subsequent disease-directed treatment. No new safety signal was identified during the disclosed follow-up, although that finding should not be interpreted as proof that the treatment is risk-free.
The more practical question is whether diagnostic testing, PD-L1 assessment, imaging, trial consent and repeated treatment can be integrated without creating harmful delays. In the previous study, the median time from randomization to surgery was approximately 35 days in Multikine-treated groups and 12 days in controls. The publication reported no presurgical deaths and no treatment-emergent event that prevented surgery, but participating centers in the confirmatory study will still need disciplined scheduling.
Head and neck cancer care already requires coordination among surgeons, medical oncologists, radiation oncologists, pathologists, radiologists and dental or nutritional specialists. Multikine would add biomarker selection and repeated presurgical administration to that pathway. The operational burden may be manageable at experienced trial centers, but commercial adoption would ultimately require a workflow that can be reproduced beyond specialist institutions.
Why will manufacturing and global study execution matter as much as enrollment?
Multikine is more complex to manufacture and characterize than a conventional small-molecule drug. CEL-SCI produces the investigational biologic through a controlled process involving cultured peripheral blood mononuclear cells and operates a dedicated manufacturing facility near Baltimore, Maryland.
For registration, regulators will examine whether the product used across different countries and clinical sites is consistent in identity, potency, purity and biological activity. Lot comparability, raw-material controls, viral safety, cold-chain management and validated release testing will all form part of the eventual approval package.
Global enrollment may improve recruitment speed and population diversity, but it also increases execution demands. PD-L1 testing and lymph-node staging must be standardized across regions, pathology interpretation must remain consistent and investigators must apply the resectability criteria uniformly. Small differences in patient selection could have an outsized effect in a 212-patient trial designed around a large expected survival advantage.
Orient EuroPharma’s commitment to oversee and finance enrollment in Taiwan reduces part of CEL-SCI’s direct burden. Even so, the company remains responsible for regulatory compliance, data quality and the integrity of the overall study.
Can CEL-SCI finance the confirmatory study without continuing dilution pressure?
Financing remains one of the programme’s clearest commercial risks. CEL-SCI reported cash and cash equivalents of approximately US$1.9 million at March 31, 2026, a six-month operating loss of about US$10.7 million and substantial doubt about its ability to continue as a going concern. The company has estimated that the confirmatory registration study could cost approximately US$30 million to US$35 million.
CEL-SCI subsequently raised gross proceeds of approximately US$7.2 million through a May 2026 offering and another US$2.5 million through a June offering. Those transactions strengthened liquidity enough to support further development, but placement fees and expenses reduced the usable proceeds, and the combined amount remains below the estimated trial cost.
The funding position means enrollment progress and capital strategy are inseparable. Additional equity issuance could dilute existing shareholders, while slower fundraising could delay site activation or recruitment. A licensing transaction, regional partnership or non-dilutive financing arrangement could reduce that pressure, but such support should not be assumed until binding terms and funding commitments are disclosed.
CEL-SCI shares closed at US$1.22 on July 13, down 11.6% in the session following the trial announcement. The stock was down about 4.7% over five trading days but remained approximately 20.8% higher over one month. It traded within a 52-week range of US$0.89 to US$13.48 and had lost roughly three-quarters of its value during 2026, reflecting the volatility, financing exposure and clinical uncertainty typical of a small biotechnology company.
The announcement’s timing does not prove that the trial launch caused the daily decline. The muted market response nevertheless indicates that investors are not treating the start of the confirmatory programme as equivalent to clinical or regulatory de-risking.
What milestones would turn the Multikine launch into credible registration progress?
The next meaningful milestones will be activated clinical sites, publication of the final registry record, first-patient enrollment and evidence that screening can identify eligible patients at an acceptable rate. The combination of no clinical lymph-node involvement, resectable locally advanced disease and low or zero PD-L1 expression may produce a smaller recruitment pool than the headline incidence of head and neck cancer suggests.
After enrollment begins, the market will need clarity on recruitment speed, regional participation, protocol adherence, manufacturing supply and the financing required to reach full enrollment. Any accelerated approval strategy will depend on the quality of the presurgical response data and continued regulatory agreement on how those findings relate to long-term benefit.
CEL-SCI has designed the new study to answer the criticism left by the earlier primary endpoint miss: whether Multikine’s survival signal can be reproduced in patients identified prospectively before treatment. If that happens, the company would have a credible basis for discussing registration in a defined population. Until then, the 212-patient launch is best understood as the beginning of the decisive experiment, not the final step before Multikine reaches the market.
